Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Open in Screener

LQDA

Liquidia Corp

May 17 • 04:00PM ET

12.71

Dollar change -0.03
Percentage change -0.24	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWO DWAS VTWO PTH VHT IWN IWC

Index	RUT	P/E	-	EPS (ttm)	-1.57	Insider Own	36.20%	Shs Outstand	68.63M	Perf Week	5.39%
Market Cap	970.79M	Forward P/E	-	EPS next Y	-0.44	Insider Trans	5.52%	Shs Float	48.73M	Perf Month	-7.97%
Income	-107.69M	PEG	-	EPS next Q	-0.34	Inst Own	51.33%	Short Float	16.65%	Perf Quarter	-12.89%
Sales	15.97M	P/S	60.79	EPS this Y	-11.93%	Inst Trans	-4.04%	Short Ratio	9.95	Perf Half Y	97.67%
Book/sh	1.13	P/B	11.24	EPS next Y	67.38%	ROA	-66.06%	Short Interest	8.11M	Perf Year	62.74%
Cash/sh	2.07	P/C	6.15	EPS next 5Y	-	ROE	-128.27%	52W Range	5.71 - 16.99	Perf YTD	5.65%
Dividend Est.	-	P/FCF	-	EPS past 5Y	30.44%	ROI	-121.99%	52W High	-25.19%	Beta	0.25
Dividend TTM	-	Quick Ratio	7.50	Sales past 5Y	423.30%	Gross Margin	68.89%	52W Low	122.59%	ATR (14)	0.62
Dividend Ex-Date	-	Current Ratio	7.66	EPS Y/Y TTM	-172.43%	Oper. Margin	-582.16%	RSI (14)	45.54	Volatility	5.16% 4.69%
Employees	136	Debt/Eq	0.04	Sales Y/Y TTM	-5.72%	Profit Margin	-674.42%	Recom	1.57	Target Price	24.14
Option/Short	Yes / Yes	LT Debt/Eq	0.02	EPS Q/Q	-198.95%	Payout	-	Rel Volume	0.81	Prev Close	12.74
Sales Surprise	-33.58%	EPS Surprise	-66.92%	Sales Q/Q	-33.85%	Earnings	May 14 BMO	Avg Volume	815.39K	Price	12.71
SMA20	0.54%	SMA50	-9.44%	SMA200	23.85%	Trades		Volume	661,341	Change	-0.24%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-05-24	Reiterated	Needham	Buy	$18 → $28
Sep-19-22	Resumed	Wedbush	Underperform	$3
Sep-01-22	Downgrade	Wedbush	Neutral → Underperform	$3
Jul-22-22	Initiated	Ladenburg Thalmann	Buy	$15
May-31-22	Initiated	BTIG Research	Buy	$14
May-26-22	Initiated	BofA Securities	Buy	$12
Dec-04-20	Initiated	H.C. Wainwright	Buy	$6
Nov-20-20	Downgrade	Wedbush	Outperform → Neutral	$20 → $4
Nov-08-18	Resumed	Jefferies	Buy
Sep-05-18	Initiated	Wedbush	Outperform	$26
Aug-20-18	Initiated	Needham	Buy	$30
Aug-20-18	Initiated	Jefferies	Buy	$22

Show Previous Ratings

May-15-24 03:03AM	Liquidia Corp (LQDA) Q1 2024 Earnings Call Transcript Highlights: A Detailed Review of ... (GuruFocus.com)
02:05AM	Q1 2024 Liquidia Corp Earnings Call (Thomson Reuters StreetEvents)
May-14-24 09:35AM	Down -11.26% in 4 Weeks, Here's Why You Should You Buy the Dip in Liquidia Technologies (LQDA) (Zacks)
08:53AM	LQDA Stock Earnings: Liquidia Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
May-13-24 05:43PM	Liquidia Corporation Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
08:00AM	Loading…
May-10-24 08:00AM	Liquidia Announces Poster Presentation at the American Thoracic Society (ATS) 2024 International Conference on Its Open-Label Safety Study of L606 (Liposomal Treprostinil) in Patients with PAH and PH-ILD (GlobeNewswire)
May-07-24 08:30AM	Liquidia Corporation to Present at BofA Securities Health Care Conference 2024 (GlobeNewswire)
08:00AM	Liquidia Corporation to Report First Quarter 2024 Financial Results on May 14, 2024 (GlobeNewswire)
Apr-25-24 10:02AM	Earnings Preview: Liquidia Technologies, Inc. (LQDA) Q1 Earnings Expected to Decline (Zacks)
Apr-02-24 09:00AM	Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-01-24 06:00AM	Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA (treprostinil) inhalation powder (GlobeNewswire)
Mar-20-24 01:50AM	Chief Medical Officer Rajeev Saggar Sells Shares of Liquidia Corp (LQDA) (GuruFocus.com)
01:49AM	Insider Sell: CFO and COO Michael Kaseta Sells 12,166 Shares of Liquidia Corp (LQDA) (GuruFocus.com)
Mar-16-24 02:42PM	Liquidia Corporation (NASDAQ:LQDA) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-13-24 10:54PM	Q4 2023 Liquidia Corp Earnings Call (Thomson Reuters StreetEvents) +5.36%
07:31AM	Loading…
07:31AM	Liquidia Corp (LQDA) Reports Full Year 2023 Financial Results (GuruFocus.com)
07:10AM	Liquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
06:00AM	Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-06-24 06:30AM	Liquidia Corporation to Report Full Year 2023 Financial Results on Wednesday, March 13, 2024 (GlobeNewswire)
Feb-21-24 03:17PM	United Therapeutics' Challenges FDA Over Liquidia's Drug Approval Process, Clocks Strong Q4 Earnings (Benzinga)
06:51AM	UPDATE 3-United Therapeutics starts litigation with FDA over rival Liquidia's drug application (Reuters)
06:24AM	United Therapeutics, in unusual step, sues FDA over rivals drug application (BioPharma Dive)
Jan-30-24 06:30AM	Liquidia Corporation Announces Poster Presentation at the Pulmonary Vascular Research Institute 2024 Annual Congress (GlobeNewswire)
Jan-29-24 09:55AM	Wall Street Analysts Think Liquidia Technologies, Inc. (LQDA) Could Surge 71.41%: Read This Before Placing a Bet (Zacks)
Jan-25-24 06:25AM	UPDATE 1-US FDA still reviewing Liquidia's inhaled blood pressure drug (Reuters)
06:00AM	Liquidia Corporation Provides Update on New Drug Application for YUTREPIA (treprostinil) inhalation powder (GlobeNewswire)
Jan-19-24 06:30AM	Liquidia Corporation Announces Updates to Operations Leadership (GlobeNewswire)
Jan-09-24 06:21PM	Wall Street Analysts Believe Liquidia Technologies, Inc. (LQDA) Could Rally 29.94%: Here's is How to Trade (Zacks)
04:56PM	What Makes Liquidia Technologies, Inc. (LQDA) a Strong Momentum Stock: Buy Now? (Zacks)
Jan-08-24 08:22AM	Liquidia Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims (GlobeNewswire)
06:45AM	Loading…
Jan-05-24 06:45AM	Liquidia Provides Update on Clinical Pipeline Targeting PAH and PH-ILD (GlobeNewswire)
Jan-04-24 09:10AM	Liquidia Corporation Announces $100 Million in New Financings (GlobeNewswire) +7.97%
Jan-02-24 06:45AM	Liquidia Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-29-23 06:45AM	16 Most Promising Long-Term Stocks According to Analysts (Insider Monkey)
Dec-25-23 08:00AM	Biotech CEOs Are Buying Up Their Surging Stocks (Barrons.com)
Dec-22-23 06:35PM	Peabody Energy, Janus International, and More Stocks See Action From Activist Investors (Barrons.com)
Dec-20-23 04:56PM	U.S. Federal Circuit Affirms Earlier PTAB Decision to Invalidate All Claims of United Therapeutics Patent No. 10,716,793 ('793 Patent) (GlobeNewswire) +35.70%
Dec-19-23 01:02PM	Insider Sell Alert: Chief Medical Officer Rajeev Saggar Sells 14,887 Shares of Liquidia Corp (LQDA) (GuruFocus.com) +5.63%
Dec-12-23 07:13AM	Liquidia Announces Pricing of Public Offering of Common Stock (GlobeNewswire)
Nov-08-23 10:47AM	Liquidia Corporation (NASDAQ:LQDA) Q3 2023 Earnings Call Transcript (Insider Monkey)
12:44AM	Q3 2023 Liquidia Corp Earnings Call (Thomson Reuters StreetEvents)
Nov-07-23 07:07AM	Liquidia Corp (LQDA) Reports Q3 2023 Financial Results (GuruFocus.com)
06:30AM	Liquidia Corporation Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-31-23 06:30AM	Liquidia Corporation to Report Third Quarter 2023 Financial Results on November 7, 2023 (GlobeNewswire)
Oct-02-23 07:00AM	Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors (GlobeNewswire)
Sep-25-23 04:09PM	FDA Accepts Submission to Add PH-ILD to YUTREPIA Label (GlobeNewswire)
Sep-06-23 04:30PM	United Therapeutics Corporation Files Lawsuit Alleging Infringement of Tyvaso Patent Already Found to Be Invalid by U.S. Patent Office (GlobeNewswire)
Aug-13-23 05:22AM	Liquidia Corporation (NASDAQ:LQDA) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-11-23 12:38AM	Q2 2023 Liquidia Corp Earnings Call (Thomson Reuters StreetEvents) -9.13%
Aug-10-23 07:15AM	Liquidia Technologies, Inc. (LQDA) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
06:00AM	Liquidia Corporation Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-03-23 08:17AM	Liquidia Corporation to Report Second Quarter 2023 Financial Results on August 10, 2023 (GlobeNewswire)
Jul-27-23 09:13AM	Liquidia Stock Down 12% But Insiders Still In US$74k Profit (Simply Wall St.)
06:00AM	Liquidia Submits Amendment to Add PH-ILD Indication to Tentatively Approved NDA for YUTREPIA (treprostinil) Inhalation Powder (GlobeNewswire)
Jul-25-23 02:37PM	Liquidia stock drops after setback in United Therapeutics dispute (American City Business Journals)
08:25AM	Silver Spring's United Therapeutics claims victory in patent infringement suit against Liquidia (American City Business Journals)
Jul-24-23 01:46PM	U.S. Federal Circuit Affirms All District Court Rulings in Patent Litigation (GlobeNewswire) -12.76%
Jun-29-23 11:24AM	Liquidia (LQDA) Up on Deal With Pharmosa to Co-Develop PH Drug (Zacks) -17.68%
Jun-28-23 05:36AM	Liquidia Corporation and Pharmosa Biopharm Announce Collaboration for Sustained-Release Inhaled Treprostinil Product in North America (GlobeNewswire) +10.99%
May-31-23 06:30AM	Liquidia Corporation to Present at the 2023 Jefferies Healthcare Conference (GlobeNewswire)
May-30-23 11:26AM	Investing in Liquidia (NASDAQ:LQDA) a year ago would have delivered you a 106% gain (Simply Wall St.)
May-21-23 03:39PM	Hero or Zero? 7 High-Risk Stocks to Make You Rich Or Broke. (InvestorPlace)
May-19-23 06:15AM	Liquidia Announces Poster Presentation at the 2023 American Thoracic Society International Conference (GlobeNewswire) +6.14%
May-09-23 06:33AM	Institutional investors are Liquidia Corporation's (NASDAQ:LQDA) biggest bettors and were rewarded after last week's US$60m market cap gain (Simply Wall St.)
May-04-23 09:15AM	Liquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
06:30AM	Liquidia Corporation Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-02-23 06:45AM	Liquidia Corporation to Present at BofA Securities 2023 Health Care Conference (GlobeNewswire)
Apr-27-23 06:45AM	Liquidia Corporation to Report First Quarter 2023 Financial Results on May 4, 2023 (GlobeNewswire)
Apr-20-23 04:17AM	Strength Seen in EyePoint Pharmaceuticals (EYPT): Can Its 9.6% Jump Turn into More Strength? (Zacks)
Apr-18-23 08:33AM	Liquidia Corporation's (NASDAQ:LQDA) Earnings Haven't Escaped The Attention Of Investors (Simply Wall St.)
Apr-11-23 06:45AM	Liquidia Corporation to Present at 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-03-23 06:45AM	Liquidia and GSK Restructure License to PRINT Technology for Inhaled Applications (GlobeNewswire)
Mar-25-23 08:33AM	Industry Analysts Just Made A Captivating Upgrade To Their Liquidia Corporation (NASDAQ:LQDA) Revenue Forecasts (Simply Wall St.)
Mar-20-23 04:10AM	Liquidia Corporation (NASDAQ:LQDA) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-18-23 08:34AM	Liquidia Full Year 2022 Earnings: Beats Expectations (Simply Wall St.)
Mar-17-23 03:22AM	Q4 2022 Liquidia Corp Earnings Call (Thomson Reuters StreetEvents)
Mar-16-23 07:55AM	Liquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +15.25%
06:30AM	Liquidia Corporation Reports Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-09-23 10:00AM	Liquidia Technologies, Inc. (LQDA) May Report Negative Earnings: Know the Trend Ahead of Q4 Release (Zacks) -5.41%
07:19AM	Liquidia Corporation to Report Full Year 2022 Financial Results on Thursday, March 16, 2023 (GlobeNewswire)
Feb-17-23 07:33AM	Insiders saw their US$2.6m investment bump up to US$4.2m after Liquidia Corporation (NASDAQ:LQDA) soared 15% last week (Simply Wall St.)
Feb-05-23 08:49PM	Decision moves Liquidia, United Therapeutics patent dispute toward resolution (American City Business Journals)
Feb-03-23 05:10AM	Strength Seen in Liquidia Technologies, Inc. (LQDA): Can Its 9.7% Jump Turn into More Strength? (Zacks)
Feb-02-23 04:39PM	Patent Trial and Appeal Board (PTAB) Reaffirms Decision to Invalidate All Claims of United Therapeutics (UTHR) Patent No. 10,716,793 (793 Patent) (GlobeNewswire) +9.70%
06:30AM	Liquidia Corporation Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-09-23 10:01PM	Liquidia inks $100M financing agreement amid patent dispute (American City Business Journals)
06:30AM	Liquidia Enters Into a Revenue Interest Financing Agreement With HealthCare Royalty for Up to $100 Million (GlobeNewswire)
Dec-30-22 09:40AM	Are Medical Stocks Lagging Assertio (ASRT) This Year? (Zacks)
Dec-14-22 09:40AM	Are Medical Stocks Lagging Assertio (ASRT) This Year? (Zacks)
Dec-05-22 04:05PM	Liquidia Announces Collaboration to Develop a New Infusion Pump for Subcutaneous Delivery of Treprostinil Injection to Treat Pulmonary Arterial Hypertension (PAH) (GlobeNewswire) -5.65%
Dec-01-22 09:55AM	Wall Street Analysts Think Liquidia Technologies, Inc. (LQDA) Could Surge 153%: Read This Before Placing a Bet (Zacks) +5.78%
Nov-28-22 09:40AM	Is Liquidia Technologies (LQDA) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-08-22 07:45AM	Liquidia Technologies, Inc. (LQDA) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
06:30AM	Liquidia Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-02-22 10:15AM	ANAVASI DIAGNOSTICS ANNOUNCES NEWLY ELECTED OUTSIDE BOARD OF DIRECTORS (PR Newswire)
Nov-01-22 06:45AM	Liquidia to Report Third Quarter 2022 Financial Results on November 8, 2022 (GlobeNewswire) +5.93%
Oct-27-22 04:10PM	Precedential Opinion Panel Denies United Therapeutics Request for Review of 793 Inter Partes Review Decision (GlobeNewswire)
Oct-26-22 09:40AM	Are Medical Stocks Lagging Acadia Healthcare (ACHC) This Year? (Zacks)
Oct-17-22 06:30AM	Liquidia Announces Presentations at the CHEST 2022 Annual Meeting (GlobeNewswire)
Sep-26-22 06:45AM	7 Momentum Stocks to Buy Now for Extraordinary Gains (InvestorPlace)

Liquidia Corp. operates as a holding company which through its subsidiary engages in developing and commercializing biopharmaceutical products. It engages in novel products development used in PRINT technology to transform the lives of patients. The company was founded on June 28, 2020, and is headquartered in Morrisville, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Saggar Rajeev	Chief Medical Officer	Apr 19 '24	Sale	13.68	1,649	22,558	211,672	Apr 23 05:24 PM
JEFFS ROGER	Chief Executive Officer	Apr 12 '24	Sale	14.58	8,360	121,889	826,985	Apr 16 05:15 PM
Kaseta Michael	CFO and COO	Apr 12 '24	Sale	14.58	3,136	45,723	315,045	Apr 16 05:16 PM
Schundler Russell	General Counsel	Apr 12 '24	Sale	14.58	2,060	30,035	486,027	Apr 16 05:17 PM
Moomaw Scott	Chief Commercial Officer	Apr 12 '24	Sale	14.58	1,585	23,109	151,881	Apr 16 05:16 PM
Saggar Rajeev	Chief Medical Officer	Apr 12 '24	Sale	14.58	1,525	22,234	213,321	Apr 16 05:17 PM
Adair Jason	Chief Business Officer	Apr 12 '24	Sale	14.58	1,189	17,336	111,537	Apr 15 08:31 PM
JEFFS ROGER	Chief Executive Officer	Mar 18 '24	Sale	15.82	28,583	452,183	835,345	Mar 19 09:46 PM
Kaseta Michael	CFO and COO	Mar 18 '24	Sale	15.82	12,166	192,466	318,181	Mar 19 09:47 PM
Schundler Russell	General Counsel	Mar 18 '24	Sale	15.82	8,653	136,890	488,087	Mar 19 09:48 PM
Saggar Rajeev	Chief Medical Officer	Mar 18 '24	Sale	15.82	7,530	119,125	214,846	Mar 19 09:46 PM
Moomaw Scott	Chief Commercial Officer	Mar 18 '24	Sale	15.82	6,108	96,629	153,466	Mar 19 09:47 PM
Adair Jason	Chief Business Officer	Mar 18 '24	Sale	15.81	4,657	73,649	108,640	Mar 19 09:50 PM
Moomaw Scott	Chief Commercial Officer	Feb 29 '24	Sale	14.17	546	7,737	159,574	Mar 04 07:07 PM
Adair Jason	Chief Business Officer	Feb 29 '24	Sale	14.17	455	6,447	97,412	Mar 04 07:05 PM
Adair Jason	Chief Business Officer	Dec 18 '23	Sale	7.70	77	593	54,932	Dec 20 05:20 PM
Caligan Partners LP	Director	Dec 14 '23	Buy	7.16	1,117,318	7,999,997	11,280,945	Dec 14 04:42 PM
Manning Paul B	Director	Dec 14 '23	Buy	7.16	279,330	2,000,003	279,330	Dec 18 05:00 PM
JEFFS ROGER	Chief Executive Officer	Dec 14 '23	Buy	7.16	139,665	1,000,001	640,805	Dec 18 05:02 PM
Moomaw Scott	Chief Commercial Officer	Nov 30 '23	Sale	7.28	542	3,946	106,737	Dec 05 09:18 PM
Lippe Robert A	Chief Operations Officer	Nov 30 '23	Sale	7.28	497	3,618	193,788	Dec 05 09:21 PM
Adair Jason	Chief Business Officer	Nov 30 '23	Sale	7.28	452	3,291	54,478	Dec 05 09:15 PM
Adair Jason	Chief Business Officer	Sep 19 '23	Sale	6.51	75	488	53,637	Sep 20 06:14 PM
Moomaw Scott	Chief Commercial Officer	Aug 31 '23	Sale	6.88	537	3,695	105,404	Sep 05 08:10 PM
Lippe Robert A	Chief Operations Officer	Aug 31 '23	Sale	6.88	505	3,474	192,567	Sep 05 08:11 PM
Adair Jason	Chief Business Officer	Aug 31 '23	Sale	6.88	445	3,062	53,452	Sep 05 08:09 PM
Moomaw Scott	Chief Commercial Officer	May 31 '23	Sale	8.08	651	5,260	102,268	Jun 02 05:05 PM
Lippe Robert A	Chief Operations Officer	May 31 '23	Sale	8.08	597	4,824	189,646	Jun 02 05:03 PM

Dollar change -0.08
Percentage change -2.44	%

ALIM Alimera Sciences Inc. daily Stock Chart

Held by: VXF VTI

Index	-	P/E	-	EPS (ttm)	-1.57	Insider Own	9.92%	Shs Outstand	52.35M	Perf Week	-9.99%
Market Cap	167.65M	Forward P/E	16.84	EPS next Y	0.19	Insider Trans	0.00%	Shs Float	47.19M	Perf Month	-6.98%
Income	-22.66M	PEG	-	EPS next Q	-0.04	Inst Own	83.47%	Short Float	0.26%	Perf Quarter	-6.43%
Sales	90.22M	P/S	1.86	EPS this Y	83.97%	Inst Trans	0.45%	Short Ratio	1.79	Perf Half Y	-2.74%
Book/sh	0.78	P/B	4.12	EPS next Y	250.00%	ROA	-21.34%	Short Interest	0.12M	Perf Year	55.34%
Cash/sh	0.27	P/C	11.68	EPS next 5Y	-	ROE	-197.04%	52W Range	1.86 - 4.38	Perf YTD	-25.93%
Dividend Est.	-	P/FCF	-	EPS past 5Y	21.42%	ROI	-20.21%	52W High	-26.94%	Beta	1.16
Dividend TTM	-	Quick Ratio	2.51	Sales past 5Y	13.40%	Gross Margin	74.16%	52W Low	72.03%	ATR (14)	0.26
Dividend Ex-Date	-	Current Ratio	2.62	EPS Y/Y TTM	35.82%	Oper. Margin	-0.33%	RSI (14)	39.05	Volatility	7.29% 8.14%
Employees	159	Debt/Eq	1.78	Sales Y/Y TTM	61.75%	Profit Margin	-25.12%	Recom	1.00	Target Price	8.00
Option/Short	Yes / Yes	LT Debt/Eq	1.76	EPS Q/Q	83.77%	Payout	-	Rel Volume	0.64	Prev Close	3.28
Sales Surprise	3.44%	EPS Surprise	-111.64%	Sales Q/Q	69.87%	Earnings	May 14 BMO	Avg Volume	67.94K	Price	3.20
SMA20	-8.64%	SMA50	-13.72%	SMA200	-9.30%	Trades		Volume	43,467	Change	-2.44%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-25-24	Initiated	Maxim Group	Buy	$10
Oct-30-23	Upgrade	Alliance Global Partners	Neutral → Buy	$8
May-28-19	Initiated	Craig Hallum	Buy
Apr-27-17	Initiated	Rodman & Renshaw	Buy	$4
Nov-17-14	Initiated	Summer Street Research	Buy	$12
Sep-29-14	Reiterated	Northland Capital	Outperform	$7 → $10
Oct-28-13	Upgrade	Cowen	Market Perform → Outperform
Oct-08-13	Initiated	Northland Capital	Outperform	$5
Nov-14-11	Downgrade	Rodman & Renshaw	Mkt Outperform → Mkt Perform
Dec-27-10	Reiterated	Oppenheimer	Outperform	$16 → $14
Oct-11-10	Initiated	Rodman & Renshaw	Mkt Outperform	$13
Jun-02-10	Initiated	Oppenheimer	Outperform	$16

Show Previous Ratings

May-15-24 03:06AM	Alimera Sciences Inc (ALIM) Q1 2024 Earnings Call Transcript Highlights: Soaring Revenues and ... (GuruFocus.com)
May-14-24 11:53AM	ALIM Stock Earnings: Alimera Sciences Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace) -5.75%
08:40AM	Alimera Sciences (ALIM) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:38AM	Alimera Sciences: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	Alimera Sciences Reports First Quarter 2024 Results (GlobeNewswire)
08:00AM	Loading…
May-07-24 08:00AM	Alimera Announces Scientific Data Highlighting YUTIQ to be Presented at Upcoming Association for Research in Vision and Ophthalmology and Retina World Congress Conferences (GlobeNewswire)
Apr-30-24 08:00AM	Alimera Sciences to Report First Quarter 2024 Financial Results on May 14, 2024, and Provide Corporate Update (GlobeNewswire)
Mar-20-24 08:00AM	Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-19-24 08:00AM	Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network (GlobeNewswire)
Mar-08-24 10:05AM	Alimera Sciences, Inc. (NASDAQ:ALIM) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-07-24 11:18PM	Q4 2023 Alimera Sciences Inc Earnings Call (Thomson Reuters StreetEvents)
01:55PM	Alimera Sciences Inc (ALIM) Reports Significant Revenue Growth in Q4 and Full Year 2023 (GuruFocus.com)
12:52PM	ALIM Stock Earnings: Alimera Sciences Beats Revenue for Q4 2023 (InvestorPlace)
09:00AM	Alimera Sciences (ALIM) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:11AM	Alimera Sciences: Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	Loading…
07:30AM	Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results (GlobeNewswire)
Feb-29-24 08:00AM	Alimera Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024, and Provide Corporate Update (GlobeNewswire) +5.99%
Feb-08-24 08:00AM	The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN (GlobeNewswire)
Jan-04-24 08:00AM	Alimera Completes Recruitment for the Synchronicity Study (GlobeNewswire)
Jan-02-24 08:00AM	Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.56%
Dec-12-23 07:30AM	Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-08-23 04:30PM	Alimera Appoints Maggie A. Pax to Its Board of Directors (GlobeNewswire)
Oct-31-23 08:00AM	Alimera Announces Scientific Data Highlighting ILUVIEN To Be Presented at the American Academy of Ophthalmology (GlobeNewswire)
Oct-27-23 09:26AM	Alimera Sciences, Inc. (NASDAQ:ALIM) Q3 2023 Earnings Call Transcript (Insider Monkey)
Oct-26-23 09:29AM	Alimera Sciences Inc (ALIM) Reports Q3 2023 Financial Results (GuruFocus.com)
08:30AM	Alimera Sciences (ALIM) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:18AM	Alimera Sciences: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Alimera Sciences Reports Third Quarter 2023 Results (GlobeNewswire)
Oct-16-23 08:00AM	Alimera Sciences to Report Third Quarter 2023 Financial Results on October 26, 2023, and Provide Corporate Update (GlobeNewswire) +14.83%
Oct-11-23 08:00AM	Alimera Announces Multiple Presentations Highlighting ILUVIEN and YUTIQ Data at Retina Society Annual Congress (GlobeNewswire) -5.75%
08:00AM	Loading…
Oct-03-23 08:00AM	Alimera Sciences Appoints Jason Werner as Chief Operating Officer (GlobeNewswire)
Sep-16-23 03:01AM	Caligan Partners LP Reduces Stake in Alimera Sciences Inc (GuruFocus.com)
Sep-05-23 08:00AM	Alimera Sciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) -7.04%
Aug-23-23 09:02AM	Altium Capital Management LP Acquires New Stake in Alimera Sciences Inc (GuruFocus.com)
Aug-13-23 04:37AM	Alimera Sciences, Inc. (NASDAQ:ALIM) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-11-23 06:21AM	Stonepine Capital Management, LLC Acquires New Stake in Alimera Sciences Inc (GuruFocus.com)
Aug-10-23 10:00PM	Q2 2023 Alimera Sciences Inc Earnings Call (Thomson Reuters StreetEvents) +7.03%
08:50AM	Alimera Sciences (ALIM) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:47AM	Alimera Sciences: Q2 Earnings Snapshot (AP Finance)
07:30AM	Alimera Sciences Reports Second Quarter 2023 Results (GlobeNewswire)
Aug-08-23 09:15AM	Stonegate Capital Partners Announces Publishing of a Thematic Report - Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline (Newsfile)
Aug-03-23 07:03PM	Velan Capital Investment Management LP Boosts Stake in Alimera Sciences Inc (GuruFocus.com) +6.45%
Aug-02-23 11:43AM	Alimera Sciences to Report Second Quarter 2023 Financial Results on August 10, 2023, and Provide Corporate Update (GlobeNewswire) -5.20%
Jul-07-23 09:40AM	Are Medical Stocks Lagging 89BIO (ETNB) This Year? (Zacks)
Jun-08-23 08:50AM	Alimera Sciences (ALIM) Is Attractively Priced Despite Fast-paced Momentum (Zacks) -5.15%
Jun-01-23 09:40AM	Are Medical Stocks Lagging Alimera Sciences (ALIM) This Year? (Zacks) -5.09%
May-25-23 10:15AM	Alimera (ALIM) Completes Enrollment in Eye Disease Study (Zacks)
May-24-23 08:00AM	Alimera Completes Recruitment for its Landmark NEW DAY Study (GlobeNewswire) +8.09%
May-23-23 08:50AM	Alimera Sciences (ALIM) Shows Fast-paced Momentum But Is Still a Bargain Stock (Zacks) -7.84%
May-19-23 12:01PM	Alimera (ALIM) Up on Deal With Eyepoint for U.S. Rights to Yutiq (Zacks) -6.50%
May-18-23 10:29PM	Q1 2023 Alimera Sciences Inc Earnings Call (Thomson Reuters StreetEvents) +19.42%
09:02AM	EyePoint Pharma Offloads Its Commercially-Available Eye Implant For $82.5M Plus Royalties (Benzinga)
07:00AM	Alimera Acquires U.S. Commercial Rights to YUTIQ® (GlobeNewswire)
May-17-23 04:05PM	Alimera Sciences to Host Rescheduled Corporate Update Call on Thursday, May 18, 2023, at 8:30am ET (GlobeNewswire) +9.57%
May-15-23 09:05AM	Alimera Sciences (ALIM) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:50AM	Alimera Sciences Reports First Quarter 2023 Results (GlobeNewswire)
May-08-23 08:00AM	Alimera Sciences to Report First Quarter 2023 Financial Results on May 15, 2023, and Provide Corporate Update (GlobeNewswire) -5.26%
May-01-23 10:01AM	Will Alimera Sciences (ALIM) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-20-23 08:00AM	Alimera Data to be Featured in Scientific Programming at Upcoming Annual Congress (GlobeNewswire)
Apr-17-23 07:20AM	There's No Escaping Alimera Sciences, Inc.'s (NASDAQ:ALIM) Muted Revenues Despite A 27% Share Price Rise (Simply Wall St.)
Apr-04-23 01:18PM	Alimera Sciences, Inc. (NASDAQ:ALIM) Q4 2022 Earnings Call Transcript (Insider Monkey)
Apr-03-23 08:09AM	When Will Alimera Sciences, Inc. (NASDAQ:ALIM) Breakeven? (Simply Wall St.) -5.24%
08:00AM	Alimera Announces Expansion of Agreement with Distribution Partner Horus Pharma to Include Marketing ILUVIEN® in the Nordic Countries (GlobeNewswire)
Mar-31-23 09:15AM	Alimera Sciences (ALIM) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +17.98%
08:00AM	Alimera Sciences Announces 2022 Financial Results and Business Update (GlobeNewswire)
Mar-27-23 08:00AM	Alimera Improves Capital Structure, Strengthens Balance Sheet and Extends Term Loan Facility (GlobeNewswire) +36.91%
Mar-24-23 04:05PM	Alimera Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 31, 2023, and Provide Corporate Update (GlobeNewswire)
Feb-27-23 08:00AM	Alimera Appoints Roger Sawhney, M.D. to Its Board of Directors (GlobeNewswire)
Feb-22-23 08:00AM	Alimera Announces Submission of Marketing Authorization Application in Switzerland for ILUVIEN® (GlobeNewswire) -5.44%
Jan-09-23 08:00AM	Alimera Sciences Appoints Industry Veteran Russell L. Skibsted as Chief Financial Officer (GlobeNewswire)
Dec-29-22 06:02AM	Alimera Sciences, Inc. (NASDAQ:ALIM) Q3 2022 Earnings Call Transcript (Insider Monkey) +10.76%
Dec-08-22 08:00AM	Alimera Sciences Announces Agreement to Extend Amortization Date and Interest-Only Period on Loan Agreement (GlobeNewswire)
Nov-29-22 08:00AM	Alimera Highlights Abstracts Regarding Consensus Among US Retina Specialists and Reduced Retinal Thickness Variability Leading to Improved Visual Outcomes Following ILUVIEN® Administration (GlobeNewswire)
Nov-17-22 03:54PM	7 Stocks That Could Implode at Any Moment (InvestorPlace)
Nov-16-22 05:05AM	Alimera Sciences Third Quarter 2022 Earnings: Misses Expectations (Simply Wall St.) -9.38%
Nov-14-22 08:55AM	Alimera Sciences (ALIM) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:30AM	Alimera Sciences Announces Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-02-22 08:00AM	Alimera Sciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022, and Provide Corporate Update (GlobeNewswire)
Nov-01-22 08:00AM	Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in the Czech Republic (GlobeNewswire)
Oct-20-22 09:40AM	Is Alimera Sciences (ALIM) Stock Outpacing Its Medical Peers This Year? (Zacks)
Oct-18-22 09:03AM	10 Best Low Price Pharma Stocks To Buy Now (Insider Monkey) +6.11%
Oct-06-22 08:00AM	Paladin Phase 4 Study Confirms ILUVIEN® Patients' Reduced Need for Multiple Treatments (GlobeNewswire) +6.81%
Sep-23-22 08:00AM	Alimera Announces Agreement with Jaeb Center for Health Research on Behalf of the DRCR Retina Network (GlobeNewswire)
Sep-20-22 08:00AM	Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in Ireland (GlobeNewswire)
Sep-19-22 09:40AM	Are Medical Stocks Lagging Alimera Sciences (ALIM) This Year? (Zacks)
Sep-02-22 09:40AM	Is Humana (HUM) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-31-22 08:48AM	Alimera Announces Multiple Abstracts Highlighting ILUVIEN® Real World Data at EURETINA Annual Congress (GlobeNewswire)
Aug-29-22 08:50AM	Why Fast-paced Mover Alimera Sciences (ALIM) Is a Great Choice for Value Investors (Zacks)
Aug-19-22 08:50AM	Alimera Sciences (ALIM) Is a Great Choice for "Trend" Investors, Here's Why (Zacks) +5.78%
Aug-17-22 09:40AM	Is Alimera Sciences (ALIM) Outperforming Other Medical Stocks This Year? (Zacks)
Aug-10-22 08:00AM	Alimera Sciences to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference (GlobeNewswire)
Aug-09-22 08:00AM	Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in Portugal (GlobeNewswire) -5.59%
06:47AM	Investors in Alimera Sciences (NASDAQ:ALIM) from five years ago are still down 68%, even after 32% gain this past week (Simply Wall St.)
Aug-05-22 08:50AM	Here Is Why Bargain Hunters Would Love Fast-paced Mover Alimera Sciences (ALIM) (Zacks)
Aug-01-22 09:40AM	Has Alimera Sciences (ALIM) Outpaced Other Medical Stocks This Year? (Zacks)
Jul-27-22 08:45AM	Alimera Sciences (ALIM) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +6.60%
07:30AM	Alimera Sciences Announces Second Quarter 2022 Financial Results (GlobeNewswire)
Jul-26-22 08:00AM	Paladin Phase 4 Study Confirms Safety of Durable ILUVIEN® Treatment and Reduces Burden of Care For DME Patients (GlobeNewswire)
Jul-22-22 10:34AM	Alimera Sciences to Report Second Quarter 2022 Financial Results on Wednesday, July 27, 2022, and Provide Corporate Update (GlobeNewswire)
08:00AM	Alimera Announces Pricing and Reimbursement of Uveitis Indication Granted for ILUVIEN® in France (GlobeNewswire)

Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the following geographical segments: U.S. and International. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Caligan Partners LP	10% Owner	Sep 14 '23	Buy	3.39	579,000	1,962,810	16,835,154	Sep 15 04:05 PM
Caligan Partners LP	10% Owner	Sep 14 '23	Sale	3.39	579,000	1,962,810	16,256,154	Sep 15 04:05 PM

Open in Screener

LAB

Standard BioTools Inc

May 17 • 04:00PM ET

2.57

Dollar change +0.07
Percentage change 2.80	%

Healthcare • Diagnostics & Research • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

LAB Standard BioTools Inc daily Stock Chart

Held by: ARKG VTI VXF VHT IWC DFAC ITOT FHLC AVUS DFUS

Index	-	P/E	-	EPS (ttm)	-1.00	Insider Own	3.26%	Shs Outstand	383.05M	Perf Week	7.08%
Market Cap	984.44M	Forward P/E	-	EPS next Y	-0.18	Insider Trans	14.73%	Shs Float	370.58M	Perf Month	1.18%
Income	-135.98M	PEG	-	EPS next Q	-0.08	Inst Own	69.17%	Short Float	3.08%	Perf Quarter	0.00%
Sales	126.76M	P/S	7.77	EPS this Y	64.54%	Inst Trans	-1.58%	Short Ratio	4.57	Perf Half Y	16.82%
Book/sh	1.52	P/B	1.69	EPS next Y	47.00%	ROA	-15.66%	Short Interest	11.42M	Perf Year	31.79%
Cash/sh	1.21	P/C	2.13	EPS next 5Y	-	ROE	-37.47%	52W Range	1.57 - 3.16	Perf YTD	16.29%
Dividend Est.	-	P/FCF	-	EPS past 5Y	8.72%	ROI	-22.34%	52W High	-18.67%	Beta	1.66
Dividend TTM	-	Quick Ratio	4.17	Sales past 5Y	-0.06%	Gross Margin	49.15%	52W Low	63.69%	ATR (14)	0.13
Dividend Ex-Date	-	Current Ratio	4.50	EPS Y/Y TTM	40.19%	Oper. Margin	-68.11%	RSI (14)	53.41	Volatility	3.97% 5.28%
Employees	539	Debt/Eq	0.16	Sales Y/Y TTM	31.27%	Profit Margin	-107.28%	Recom	1.00	Target Price	3.58
Option/Short	Yes / Yes	LT Debt/Eq	0.05	EPS Q/Q	-24.79%	Payout	-	Rel Volume	1.17	Prev Close	2.50
Sales Surprise	-1.01%	EPS Surprise	-140.21%	Sales Q/Q	81.30%	Earnings	May 08 AMC	Avg Volume	2.50M	Price	2.57
SMA20	4.20%	SMA50	-1.41%	SMA200	5.84%	Trades		Volume	2,935,424	Change	2.80%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-16-24	Initiated	TD Cowen	Buy	$3.50
Apr-04-24	Initiated	Jefferies	Buy	$3.25
Jul-12-23	Initiated	KeyBanc Capital Markets	Overweight	$4

May-13-24 10:45AM	Standard BioTools Inc. (NASDAQ:LAB) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-08-24 08:59PM	LAB Stock Earnings: Standard BioTools Reported Results for Q1 2024 (InvestorPlace) -5.49%
04:33PM	Standard BioTools: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Standard BioTools Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-25-24 11:27AM	Standard BioTools Initiates Restructuring Plan With 10% Workforce Reduction (MT Newswires)
08:01AM	Loading…
08:01AM	Standard BioTools Announces Operational Restructuring Plan to Drive Long-Term Profitable Growth (GlobeNewswire)
08:00AM	Standard BioTools Announces Conference Call and Webcast for First Quarter 2024 Financial Results on May 8, 2024 (GlobeNewswire)
Apr-08-24 08:00AM	Standard BioTools Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the boundaries of Tissue Imaging (GlobeNewswire) +5.11%
Apr-03-24 04:01PM	Standard BioTools Announces Multi-Year Strategic Engagement with Bristol Myers Squibb for Use of the SomaScan Platform for Translational Medicine Research (GlobeNewswire)
Mar-18-24 08:12AM	Standard BioTools Announces Exchange of All Outstanding Series B Convertible Preferred Stock for Common Stock (GlobeNewswire)
Mar-05-24 08:27AM	Standard BioTools Inc. (NASDAQ:LAB) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-29-24 06:29AM	Q4 2023 Standard BioTools Inc Earnings Call (Thomson Reuters StreetEvents) -5.06%
Feb-28-24 04:41PM	Standard BioTools Inc (LAB) Reports Growth and Margin Expansion in FY2023 Despite Economic ... (GuruFocus.com)
04:16PM	Standard BioTools: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Standard BioTools Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
08:00AM	Loading…
Feb-26-24 08:00AM	Standard BioTools and Next Gen Diagnostics Announce Partnership to Provide Complete Automation of Low-Cost Pathogen Sequencing (GlobeNewswire)
Feb-22-24 04:05PM	Standard BioTools to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-14-24 08:30AM	Standard BioTools Announces Conference Call and Webcast for Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024 (GlobeNewswire)
Feb-07-24 08:30AM	Standard BioTools and Navignostics Announce Collaboration Agreement to Advance Imaging Capabilities in Personalized Medicine (GlobeNewswire)
Jan-08-24 08:30AM	Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2023 Revenue (GlobeNewswire) +13.37%
Jan-05-24 08:46AM	Standard BioTools Completes Merger with SomaLogic, Creating a Diversified and Scaled Leader in Life Sciences Tools (GlobeNewswire)
Jan-04-24 10:23PM	Standard BioTools Stockholders Approve Merger with SomaLogic (GlobeNewswire) -5.39%
09:44PM	SomaLogic Stockholders Vote to Approve Standard BioTools Transaction at Special Meeting (PR Newswire)
Dec-29-23 05:04PM	Glass Lewis Recommends Standard BioTools Stockholders Vote FOR All Proposals Relating to Proposed Merger with SomaLogic (GlobeNewswire)
Dec-28-23 04:16PM	Dr. Larry Gold and Dr. Jason Cleveland Issue Open Letter to SomaLogic Stockholders Opposing SomaLogic's Proposed Merger with Standard BioTools (PR Newswire) +5.45%
Dec-26-23 03:59PM	SomaLogic Issues Statement Correcting Madryn Asset Management's Misleading Disclosure (PR Newswire) +7.54%
Dec-22-23 06:57PM	ISS Recommends Standard BioTools Stockholders Vote FOR All Proposals Relating to Proposed Merger with SomaLogic (GlobeNewswire)
Dec-21-23 08:00AM	SomaLogic Issues Letter to Stockholders Reiterating Recommendation for Value Maximizing Merger with Standard BioTools (GlobeNewswire)
Dec-20-23 09:00AM	Skye Fund III Issues Letter Regarding Opposition to SomaLogic's Proposed Merger with Standard BioTools (GlobeNewswire) -8.10%
Dec-17-23 03:37PM	Lowey Dannenberg, P.C. is Investigating Proposed Merger Between Standard BioTools Inc. (NASDAQ: LAB) and SomaLogic, Inc. (NASDAQ: SLGC) (GlobeNewswire)
04:32PM	Loading…
Dec-12-23 04:32PM	SomaLogic Shareholder Madryn Opposes Standard BioTools Merger (Bloomberg)
Dec-11-23 10:37AM	Lowey Dannenberg, P.C. is Investigating Proposed Merger Between Standard BioTools Inc. (NASDAQ: LAB) and SomaLogic, Inc. (NASDAQ: SLGC) (GlobeNewswire)
Dec-06-23 11:18AM	Lowey Dannenberg, P.C. is Investigating Proposed Merger Between Standard BioTools Inc. (NASDAQ: LAB) and SomaLogic, Inc. (NASDAQ: SLGC) (GlobeNewswire)
Dec-04-23 08:00AM	Standard BioTools and SomaLogic Announce Date for Special Meetings of Stockholders to Vote on Proposed Merger (GlobeNewswire)
Nov-09-23 05:54AM	Q3 2023 Somalogic Inc Earnings Call (Thomson Reuters StreetEvents) +6.84%
Nov-08-23 12:47PM	Standard BioTools Inc. (NASDAQ:LAB) Q3 2023 Earnings Call Transcript (Insider Monkey)
06:52AM	Q3 2023 Standard BioTools Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-07-23 04:23PM	Standard BioTools: Q3 Earnings Snapshot (Associated Press Finance)
04:00PM	Standard BioTools Reports Third Quarter and Year-to-Date 2023 Financial Results (GlobeNewswire)
Nov-02-23 08:30AM	Standard BioTools to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-25-23 08:30AM	Standard BioTools Announces Conference Call and Webcast of Third Quarter 2023 Financial Results on November 7, 2023 (GlobeNewswire) -10.50%
Oct-10-23 10:22AM	Moore Kuehn Encourages VERY, PNT, LAB, and LVOX Investors to Contact Law Firm (GlobeNewswire)
Oct-05-23 02:42PM	Moore Kuehn Encourages APRN, FRGI, LAB, and CPRI Investors to Contact Law Firm (PR Newswire)
Oct-04-23 06:49PM	Why SomaLogic Stock Dived by 10% on Wednesday (Motley Fool) -22.22%
08:52AM	Standard BioTools to Combine with SomaLogic in $1 Billion Merger (Bloomberg)
08:00AM	Standard BioTools and SomaLogic to Combine in All-Stock Merger Creating a Diversified Leader in Life Sciences Tools (GlobeNewswire)
Aug-09-23 09:06AM	Q2 2023 Standard BioTools Inc Earnings Call (Thomson Reuters StreetEvents) +7.56%
Aug-08-23 05:36PM	Standard BioTools: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Standard BioTools Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-26-23 04:05PM	Standard BioTools to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jul-25-23 04:05PM	Standard BioTools Announces Conference Call and Webcast for Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-13-23 07:33AM	Strong week for Standard BioTools (NASDAQ:LAB) shareholders doesn't alleviate pain of five-year loss (Simply Wall St.)
Jun-14-23 07:30AM	Standard BioTools to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jun-13-23 01:30PM	With 45% ownership, Standard BioTools Inc. (NASDAQ:LAB) has piqued the interest of institutional investors (Simply Wall St.)
May-25-23 04:05PM	Standard BioTools to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-24-23 07:11AM	With Standard BioTools Up 29%, Insider Buyers Count Their Returns \ (Simply Wall St.)
06:05AM	Jeffrey Black Spends US$194k On Standard BioTools Stock \ (Simply Wall St.)
May-18-23 07:30AM	Standard BioTools Announces NGS Library Preparation as an Upgrade on the X9 High-Throughput Genomics System (GlobeNewswire) +12.05%
May-15-23 07:30AM	Standard BioTools Appoints Jeffrey Black as Chief Financial Officer and Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +7.34%
May-10-23 02:47PM	Standard BioTools Inc. (NASDAQ:LAB) Q1 2023 Earnings Call Transcript (Insider Monkey) +12.85%
06:16AM	Q1 2023 Standard BioTools Inc Earnings Call (Thomson Reuters StreetEvents)
May-09-23 06:11PM	Standard BioTools: Q1 Earnings Snapshot (AP Finance)
04:05PM	Standard BioTools Reports First Quarter 2023 Financial Results (GlobeNewswire)
Apr-25-23 04:30PM	Standard BioTools Announces Conference Call and Webcast for First Quarter 2023 Financial Results (GlobeNewswire)
Apr-20-23 05:03PM	Standard BioTools Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-18-23 10:42AM	Standard BioTools Inc.'s (NASDAQ:LAB) Low P/S No Reason For Excitement (Simply Wall St.)
Apr-17-23 08:30AM	Standard BioTools introduces the Hyperion XTi Imaging System, breaks barriers to power significant advancement in spatial biology (GlobeNewswire)
Mar-22-23 08:30AM	Standard BioTools Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-15-23 08:30AM	Standard BioTools Announces Appointment of Fenel Eloi to Board of Directors (GlobeNewswire)
Mar-14-23 08:30AM	Standard BioTools to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum (GlobeNewswire) +11.05%
Mar-01-23 04:05PM	Standard BioTools to Present at 43rd Annual Cowen Health Care Conference (GlobeNewswire)
Feb-21-23 08:30AM	Standard BioTools Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-17-23 06:43PM	Standard BioTools Inc. (NASDAQ:LAB) Q4 2022 Earnings Call Transcript (Insider Monkey)
Feb-15-23 06:01PM	How a Peninsula biotech tools company looks to corral 'one-trick ponies' (American City Business Journals)
Feb-14-23 04:05PM	Standard BioTools Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Business Outlook (GlobeNewswire)
Feb-03-23 05:30AM	The past five years for Standard BioTools (NASDAQ:LAB) investors has not been profitable (Simply Wall St.)
Jan-31-23 08:30AM	Standard BioTools Announces Conference Call and Webcast for Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Jan-09-23 08:30AM	Standard BioTools Provides Preliminary Fourth Quarter 2022 Revenue and Business Update (GlobeNewswire) +6.45%
Jan-03-23 08:30AM	Standard BioTools Announces Appointment of Betsy Jensen as Chief Human Resources Officer (GlobeNewswire) +11.11%
Dec-24-22 08:01AM	Standard BioTools Inc. (NASDAQ:LAB) institutional owners may be pleased with recent gains after 64% loss over the past year (Simply Wall St.)
Nov-28-22 08:30AM	Standard BioTools Authorizes up to $20 Million of Share Repurchases (GlobeNewswire) +10.00%
Nov-22-22 09:20AM	Standard BioTools Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-11-22 05:02AM	Standard BioTools Third Quarter 2022 Earnings: US$0.37 loss per share (vs US$0.18 loss in 3Q 2021) (Simply Wall St.) +26.42%
Nov-08-22 04:05PM	Standard BioTools Announces Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-07-22 04:05PM	Standard BioTools and Visiopharm Announce Partnership for the Development of Complete Image Analysis Solutions to be Packaged With Hyperion and Hyperion+ Imaging Systems (GlobeNewswire) -9.82%
Oct-25-22 08:30AM	Standard BioTools Announces Conference Call and Webcast of Third Quarter 2022 Financial Results (GlobeNewswire) +14.95%
Oct-13-22 08:30AM	Ascendas Genomics Receives NMPA Approval for Use of Standard BioTools Microfluidics Technology to Advance the Development of Molecular Diagnostics in China (GlobeNewswire)
Oct-06-22 08:30AM	Standard BioTools Releases the X9 Real-Time PCR System, Its Most Productive and Flexible High-Capacity Genomics Platform (GlobeNewswire)
Aug-25-22 04:05PM	Standard BioTools Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-14-22 10:38AM	Is Standard BioTools (NASDAQ:LAB) Using Debt In A Risky Way? (Simply Wall St.)
Aug-08-22 04:02PM	Standard BioTools Announces Second Quarter 2022 Financial Results and Provides Strategic Update (GlobeNewswire) +7.94%
Jul-25-22 04:30PM	Standard BioTools Announces Conference Call and Webcast of Second Quarter 2022 Financial Results (GlobeNewswire) -6.80%
Jul-04-22 11:56AM	Shareholders in Standard BioTools (NASDAQ:LAB) have lost 86%, as stock drops 12% this past week (Simply Wall St.)
May-05-22 04:02PM	Standard BioTools Announces First Quarter 2022 Financial Results (GlobeNewswire)
Apr-22-22 04:02PM	Standard BioTools Announces Conference Call and Webcast of First Quarter 2022 Financial Results (GlobeNewswire)
Apr-11-22 08:30AM	Standard BioTools Launches Hyperion+ Imaging System, the New Standard in High-Plex Spatial Imaging (GlobeNewswire)
Apr-05-22 07:30AM	Labrador Gold Intersects 6.07 g/t Au Over 19 Metres at the Big Vein Target, Kingsway Property (GlobeNewswire) -7.02%
Mar-29-22 08:00AM	Labrador Gold Extends High-Grade Gold Mineralization to 250m Southwest of Big Vein Discovery (GlobeNewswire) +10.61%

Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. It sells preparatory and analytical instruments for mass cytometry, polymerase chain reaction, library prep, single cell genomics, and consumables including integrated fluidic circuits (IFCs), assays, and reagents. The company was founded by Stephen D. Quake and Gajus Vincent Worthington on May 19, 1999 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Casdin Partners Master Fund, L	Director	May 17 '24	Buy	2.56	352,072	902,044	45,375,821	May 17 08:11 PM
Casdin Partners Master Fund, L	Director	May 16 '24	Buy	2.54	500,000	1,270,950	45,023,749	May 17 08:11 PM
Black Jeffrey G.	SVP & Chief Financial Officer	May 15 '24	Option Exercise	0.00	52,631	0	138,615	May 16 09:07 PM
Casdin Partners Master Fund, L	Director	May 15 '24	Buy	2.57	500,000	1,282,550	44,523,749	May 17 08:11 PM
Egholm Michael	President & CEO	Apr 04 '24	Option Exercise	0.00	196,512	0	422,030	Apr 05 06:59 PM
Kim Hanjoon Alex	Chief Operating Officer	Apr 04 '24	Option Exercise	0.00	70,183	0	140,366	Apr 05 06:58 PM
Casdin Partners Master Fund, L	Director	Mar 05 '24	Buy	2.62	1,403	3,669	11,497,928	Mar 06 07:20 PM
Casdin Partners Master Fund, L	Director	Mar 04 '24	Buy	2.57	250,000	642,500	11,496,525	Mar 06 07:20 PM
Casdin Partners Master Fund, L	Director	May 19 '23	Buy	2.29	800,000	1,835,920	1,200,000	May 19 09:00 PM
Casdin Eli	Director	May 19 '23	Buy	2.29	800,000	1,835,920	1,200,000	May 19 09:02 PM
Black Jeffrey G.	SVP & Chief Financial Officer	May 19 '23	Buy	2.29	42,492	97,213	85,984	May 22 06:49 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

LQDA

Liquidia Corp

ALIM

Alimera Sciences Inc.

LAB

Standard BioTools Inc

Upgrade your FINVIZ experience